DK3113773T3 - Krystallinske former af grapiprant - Google Patents

Krystallinske former af grapiprant Download PDF

Info

Publication number
DK3113773T3
DK3113773T3 DK15758500T DK15758500T DK3113773T3 DK 3113773 T3 DK3113773 T3 DK 3113773T3 DK 15758500 T DK15758500 T DK 15758500T DK 15758500 T DK15758500 T DK 15758500T DK 3113773 T3 DK3113773 T3 DK 3113773T3
Authority
DK
Denmark
Prior art keywords
grapiprant
crystallic
forms
crystallic forms
Prior art date
Application number
DK15758500T
Other languages
English (en)
Inventor
Tamara Newbold
Melissa Smith
Chris Seekamp
Robert Wenslow
Xia Lu
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Application granted granted Critical
Publication of DK3113773T3 publication Critical patent/DK3113773T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Led Devices (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)
  • Inorganic Insulating Materials (AREA)
DK15758500T 2014-03-06 2015-03-05 Krystallinske former af grapiprant DK3113773T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949006P 2014-03-06 2014-03-06
US201461996961P 2014-07-30 2014-07-30
PCT/US2015/019043 WO2015134797A1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant

Publications (1)

Publication Number Publication Date
DK3113773T3 true DK3113773T3 (da) 2019-11-18

Family

ID=54016295

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15758500T DK3113773T3 (da) 2014-03-06 2015-03-05 Krystallinske former af grapiprant
DK19156369.1T DK3511000T3 (da) 2014-03-06 2015-03-05 Krystallinsk form x2 af grapiprant
DK17193737.8T DK3295941T3 (da) 2014-03-06 2015-03-05 Fremgangsmåde til fremstilling af form a af grapiprant

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK19156369.1T DK3511000T3 (da) 2014-03-06 2015-03-05 Krystallinsk form x2 af grapiprant
DK17193737.8T DK3295941T3 (da) 2014-03-06 2015-03-05 Fremgangsmåde til fremstilling af form a af grapiprant

Country Status (16)

Country Link
US (1) US9265756B2 (da)
EP (4) EP3113773B1 (da)
JP (2) JP6535683B2 (da)
KR (2) KR101771385B1 (da)
CN (11) CN105764508A (da)
AU (1) AU2015227064B2 (da)
CA (10) CA3168877A1 (da)
DK (3) DK3113773T3 (da)
ES (3) ES2816057T3 (da)
MX (1) MX367376B (da)
NZ (3) NZ733225A (da)
PL (3) PL3295941T3 (da)
PT (3) PT3295941T (da)
RU (1) RU2638931C1 (da)
TW (1) TWI537270B (da)
WO (1) WO2015134797A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3113774T (pt) * 2014-03-06 2022-02-28 Elanco Animal Health Incorporated Composições de grapiprant e métodos de utilização das mesmas
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
MX2007011110A (es) * 2005-03-11 2008-02-21 Pfizer Formas de cristal de un derivado de imidazol.
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
KR20090089868A (ko) * 2006-12-15 2009-08-24 글락소 그룹 리미티드 Ｅｐ４ 수용체 작동제로서 벤즈아미드 유도체
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
US9187463B2 (en) 2011-05-18 2015-11-17 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid

Also Published As

Publication number Publication date
CN107759590A (zh) 2018-03-06
KR20160106779A (ko) 2016-09-12
EP3295941B1 (en) 2020-07-22
CA2997741A1 (en) 2015-09-11
KR20170008889A (ko) 2017-01-24
KR101771385B1 (ko) 2017-08-24
CN107501262A (zh) 2017-12-22
ES2919346T3 (es) 2022-07-26
CN107759591A (zh) 2018-03-06
EP3113773A1 (en) 2017-01-11
EP3520790A1 (en) 2019-08-07
CA2997718A1 (en) 2015-09-11
US9265756B2 (en) 2016-02-23
CA2997697A1 (en) 2015-09-11
ES2816057T3 (es) 2021-03-31
JP2017507161A (ja) 2017-03-16
CA3105571A1 (en) 2015-09-11
EP3511000A1 (en) 2019-07-17
CA2997694C (en) 2021-04-06
CN107540671A (zh) 2018-01-05
CN113087705A (zh) 2021-07-09
CN105764508A (zh) 2016-07-13
CN107501263A (zh) 2017-12-22
NZ733225A (en) 2018-03-23
PT3511000T (pt) 2022-05-25
CN107573339A (zh) 2018-01-12
CA2997694A1 (en) 2015-09-11
PT3113773T (pt) 2019-11-12
ES2755396T3 (es) 2020-04-22
PL3511000T3 (pl) 2022-08-22
KR101697914B1 (ko) 2017-01-18
CN107759589A (zh) 2018-03-06
PT3295941T (pt) 2020-08-25
US20150250774A1 (en) 2015-09-10
EP3113773A4 (en) 2017-05-10
NZ733234A (en) 2018-08-31
TW201538500A (zh) 2015-10-16
CA2997746A1 (en) 2015-09-11
CA3168877A1 (en) 2015-09-11
MX2016011023A (es) 2016-11-28
CN107400132A (zh) 2017-11-28
DK3295941T3 (da) 2020-08-24
CA2997692A1 (en) 2015-09-11
MX367376B (es) 2019-08-16
DK3511000T3 (da) 2022-05-30
JP2018065819A (ja) 2018-04-26
EP3295941A1 (en) 2018-03-21
PL3113773T3 (pl) 2020-05-18
CN110256426A (zh) 2019-09-20
JP6535683B2 (ja) 2019-06-26
NZ724923A (en) 2018-03-23
TWI537270B (zh) 2016-06-11
RU2638931C1 (ru) 2017-12-19
EP3511000B1 (en) 2022-04-27
AU2015227064B2 (en) 2017-05-11
PL3295941T3 (pl) 2020-11-16
CA2997703A1 (en) 2015-09-11
AU2015227064A1 (en) 2016-10-27
WO2015134797A1 (en) 2015-09-11
CA2941019A1 (en) 2015-09-11
EP3113773B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3371171T3 (da) Inhibitorer af RET
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3201410T3 (da) Forbedringer af bygningsbeklædninger
DK3180331T3 (da) Polymorfer af selinexor
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3178817T3 (da) Amorf form af tetracyklisk forbindelse
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3132517T3 (da) Frekvenssvar
DK3514109T3 (da) Hydropyrolyse af biomasseholdige råmaterialer
DK3283210T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
DK3220891T3 (da) Sublingual formulering af riluzol
DK3304934T3 (da) Høreapparat
DK3132009T3 (da) Fremgangsmåde
DK3230255T3 (da) Regulatorer af uhæmmet adfærd
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3201323T3 (da) Modificering af bakteriofag
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK2897382T3 (da) Forbedring af binaural kilde
DK3113773T3 (da) Krystallinske former af grapiprant